Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Comparison of radon doses based on different radon monitoring approaches.
Vaupotič J, Smrekar N, Žunić ZS. Vaupotič J, et al. Among authors: smrekar n. J Environ Radioact. 2017 Apr;169-170:19-26. doi: 10.1016/j.jenvrad.2016.11.023. Epub 2016 Dec 29. J Environ Radioact. 2017. PMID: 28040622
Success and safety of high infliximab trough levels in inflammatory bowel disease.
Drobne D, Kurent T, Golob S, Svegl P, Rajar P, Terzic S, Kozelj M, Novak G, Smrekar N, Plut S, Sever N, Strnisa L, Hanzel J, Brecelj J, Urlep D, Osredkar J, Homan M, Orel R, Stabuc B, Ferkolj I, Smid A. Drobne D, et al. Among authors: smrekar n. Scand J Gastroenterol. 2018 Aug;53(8):940-946. doi: 10.1080/00365521.2018.1486882. Epub 2018 Jul 10. Scand J Gastroenterol. 2018. PMID: 29987967
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D. Hanžel J, et al. Among authors: smrekar n. United European Gastroenterol J. 2019 Jul;7(6):741-749. doi: 10.1177/2050640619840211. Epub 2019 Mar 19. United European Gastroenterol J. 2019. PMID: 31316778 Free PMC article.
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease.
Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, Koželj M, Novak G, Smrekar N, Ferkolj I, Štabuc B. Drobne D, et al. Among authors: smrekar n. Aliment Pharmacol Ther. 2019 Apr;49(7):880-889. doi: 10.1111/apt.15179. Epub 2019 Feb 19. Aliment Pharmacol Ther. 2019. PMID: 30784100
Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease.
Smrekar N, Drobne D, Smid LM, Ferkolj I, Stabuc B, Ihan A, Kopitar AN. Smrekar N, et al. Radiol Oncol. 2018 Nov 26;52(4):443-452. doi: 10.2478/raon-2018-0045. Radiol Oncol. 2018. PMID: 30511938 Free PMC article.
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
Hanžel J, Zdovc J, Kurent T, Sever N, Javornik K, Tuta K, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Grabnar I, Drobne D. Hanžel J, et al. Among authors: smrekar n. Clin Gastroenterol Hepatol. 2020 Feb 25:S1542-3565(20)30203-2. doi: 10.1016/j.cgh.2020.02.033. Online ahead of print. Clin Gastroenterol Hepatol. 2020. PMID: 32109630